Stephen A. Harrison, MD, FAASLD

The renaming of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease to metabolic dysfunction-associated steatohepatitis and metabolic dysfunction-associated steatotic liver disease is a long time coming.

BOSTON — Researchers recommended the FibroScan-aspartate aminotransferase score as a noninvasive biomarker to stratify patients at risk for metabolic dysfunction-associated steatohepatitis, when used with different cutoff points for HbA1C.

I never would have thought the debate on nonalcoholic fatty liver disease nomenclature would be as contentious as it is.

LONDON — A low-carbohydrate, high-fat diet significantly improved nonalcoholic fatty liver disease activity score and HbA1c more than a high-carbohydrate, low-fat diet in people with type 2 diabetes mellitus, according to a researcher here.

There is a significant medical need to find effective pharmacotherapies to manage NASH, the liver disease that is really a pandemic.

With the rise of the novel coronavirus in the United States, it is important for hepatologists and gastroenterologists to know how other practices are dealing with the impact of COVID-19. With nationwide shutdowns, medical institutions and practices are finding difficulties in seeing patients and researching drugs.

SAN ANTONIO — In this exclusive video from the National Liver Conference 2019, Stephen A. Harrison, MD, medical director of Pinnacle Clinical Research in San Antonio, provides an overview of the topics discussed at the meeting ranging from nonalcoholic steatohepatitis to hepatitis B to liver cancer.

Nonalcoholic steatohepatitis is an increasingly common cause of cirrhosis, hepatocellular carcinoma and liver-related mortality. Along its progression, severe nonalcoholic steatohepatitis includes the development of clinically significant or advanced fibrosis. Currently, there are no approved therapeutics to treat this disease, but that will be changing soon.